Ingrezza (Valbenazine Tosylate) Patent Expiration, LOE Window & CMS Spending

Ingrezza (Valbenazine Tosylate) by Neurocrine Biosciences: FDA Orange Book core substance LOE 2036-12-22 (last listed 2040-08-10), 1 AB generics, $2.54B 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNeurocrine Biosciences
FDA Application & PathwayN209241 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-12-22
Last Listed Patent or Exclusivity Date2040-08-10
Orange Book Patents (*PED Extensions)22 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$2.54B
2024 Medicare Part D Spend$1.96B
2024 Medicaid Spend$588.0M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 17.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.